Draxis Extends Maintenance Shutdown of Contract Manufacturing Facility
Draxis Extends Maintenance Shutdown of Contract Manufacturing Facility
Draxis Pharma, the pharmaceutical contract manufacturing division of Draxis Health Inc. (Mississauga, ON, Canada), has extended its scheduled summer maintenance shutdown of its sterile and lyophilized product manufacturing areas. The shutdown was extended to allow the company to replace a major electrical panel and a pump assembly, and to perform "further cleaning and decontamination of the sterile production area," according to a company statement. The shutdown, originally scheduled to last two to three weeks, is now expected to last five to seven weeks. Company officials declined to provide additional details until they issue a follow-up announcement about the resumption of production.
–Laura Bush
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
